GGrantIndex
Sort

48,018 grants matching immunotherapy

Shared Resource: Proteomics & Metabolomics

$374,777
Philip Robert Gafken · Fred Hutchinson Cancer Center · P30 · FY2022 · CA

Shared Resource: Proteomics & Metabolomics

$374,776
Philip Robert Gafken · Fred Hutchinson Cancer Center · P30 · FY2023 · CA

Remotely activated biomaterial scaffolds for flexibly directing the recruitment and differentiation of bone progenitor cells

$374,765
Geoffrey D Bothun · University Of Rhode Island · · FY2016 · ENG

Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors

$374,756
Deric L Wheeler · University Of Wisconsin-Madison · P50 · FY2022 · CA

Mechanistic Analysis of Anti-IgE Therapy of Asthma

$374,713
University Of Texas Sw Med Ctr/Dallas · R01 · FY2001 · AI

Effects of PGE2 on Reconstitution of Hematopoiesis and Immunity after UCBT

$374,707
Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2015 · CA

Transgenesis and Xenotransplantation

$374,700
Jorge A. Piedrahita · North Carolina State University Raleigh · R01 · FY2011 · HL

Targeted inhibition in stromal TGFβ activity in pancreatic cancer

$374,691
Rolf A Brekken · Ut Southwestern Medical Center · R01 · FY2020 · CA

Novel Biological Activities of Anti-Viral Antibody

$374,660
University Of California Irvine · R01 · FY2003 · AI

Optimal Pairing of Chemotherapy with Immunotherapy for Pancreatic Cancer

$374,645
Peter A Cohen · Mayo Clinic Rochester · P50 · FY2014 · CA

Statistical Methods for RNA-seq Data Analysis

$374,633
Wei Sun · Fred Hutchinson Cancer Research Center · R01 · FY2019 · GM

INTRATHECAL 131 I 3F8 FOR LEPTOMENINGEAL MALIGNANCIES

$374,625
Sloan-Kettering Institute For Cancer Res · R21 · FY2001 · CA

INTRATHECAL 131 I 3F8 FOR LEPTOMENINGEAL MALIGNANCIES

$374,625
Sloan-Kettering Institute For Cancer Res · R21 · FY2000 · CA

DENDRITIC CELL THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA

$374,591
Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2001 · CA

Targeting Tumor Metabolism as a Means of Enhancing Immunotherapy

$374,578
Jonathan D Powell · Johns Hopkins University · R01 · FY2020 · CA

Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy

$374,578
Drew M. Pardoll · Johns Hopkins University · R01 · FY2021 · CA

A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY

$374,578
Stephany Yi Tzeng · Johns Hopkins University · R37 · FY2021 · CA

A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY

$374,578
Stephany Yi Tzeng · Johns Hopkins University · R37 · FY2022 · CA

Correlates of antitumor immunity in colorectal cancers and anti PD1 therapy

$374,578
Franck Housseau · Johns Hopkins University · R01 · FY2020 · CA

Correlates of antitumor immunity in colorectal cancers and anti PD1 therapy

$374,578
Franck Housseau · Johns Hopkins University · R01 · FY2018 · CA

Targeting Tumor Metabolism as a Means of Enhancing Immunotherapy

$374,578
Robert David Leone · Johns Hopkins University · R01 · FY2021 · CA

A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPY

$374,578
Stephany Yi Tzeng · Johns Hopkins University · R37 · FY2020 · CA

Generating a Systemic Immune Response Using Localized Delivery of Chemotherapy in Brain Tumors

$374,578
Michael Lim · Johns Hopkins University · R01 · FY2019 · CA

Role of intratumoral high endothelial venules in tumor immunity

$374,578
Masanobu Komatsu · Johns Hopkins University · R01 · FY2022 · CA

Role of intratumoral high endothelial venules in tumor immunity

$374,578
Masanobu Komatsu · Johns Hopkins University · R01 · FY2025 · CA